Now showing items 1411-1412 of 1412
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
(John Wiley & Sons, Ltd, 2022-12)
Background and objectiveChronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT.MethodsPatients were ...
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
(Wiley Periodicals, Inc., 2022-11)